Compare Main Street Capital Corporation (MAIN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Merck & Co., Inc. — how do they compare? Main Street Capital Corporation trades at $53.67 (market cap $5.09B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 69× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (5.84%). Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 89 Days and Merck & Co., Inc. for 98 Days on average.
| MAIN | MRK | |
|---|---|---|
Market Cap | $5.09B | $351.28B |
Volume | 524,060 | 7,969,665 |
Sector | Financials | Health |
52-Week High | $64.60 | $156.43 |
52-Week Low | $49.63 | $82.49 |
Typical Hold Time | 89 Days | 98 Days |
Enterprise Value | $7.54B | $398.04B |
Dividend Yield | 5.84% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAIN trades at $54.15, down slightly over the past day. The stock shows mixed technical signals with a bearish overall trend but oversold short-term RSI. Fundamentally, the company maintains strong profitability with an 80.77% net margin and a P/E of 10.94, though revenue is expected to decline in 2026. Recent earnings have been mixed with a beat in Q2 2026 but a miss in Q1 2026.
The outlook is cautious. Analyst consensus is a Hold with a $58.33 price target, implying modest upside. Risks include softening earnings and negative operating cash flow. The dividend remains well-covered, supporting income investors, but growth prospects appear limited near-term amid a bearish technical setup.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
